Iovance Biotherapeutics to Host Second Quarter and First Half 2025 Financial Results and Corporate Updates Webcast on Thursday, August 7, 2025

Rhea-AI Summary

Iovance Biotherapeutics (NASDAQ: IOVA), a biotechnology company specializing in tumor infiltrating lymphocyte (TIL) therapies for cancer treatment, has scheduled its second quarter and first half 2025 financial results announcement for August 7, 2025.

The company will host a conference call and webcast at 4:30 p.m. ET to discuss financial performance and provide corporate updates. Investors can access the webcast through the company's website at IR.Iovance.com, with the recording remaining available for one year.

[]

SAN CARLOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its second quarter and first half 2025 financial results and corporate updates on Thursday, August 7, 2025.

Management will host a conference call and live audio webcast to discuss these results and provide a corporate update on August 7, 2025, at 4:30 p.m. ET. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/cgjzdfym. The live and archived webcast can be accessed in the Investors section of the Company’s website, IR.Iovance.com. The archived webcast will be available for one year. 

About Iovance Biotherapeutics, Inc. 

Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance’s Amtagvi^® is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit www.iovance.com.

Amtagvi ^® and its accompanying design marks, Proleukin^®, Iovance^®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.

Forward-Looking Statements

Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

CONTACTS

Investors
IR@iovance.com
650-260-7120 ext. 150

Media
PR@iovance.com 
650-260-7120 ext. 150

FAQ

When will Iovance Biotherapeutics (NASDAQ: IOVA) report Q2 2025 earnings?

Iovance Biotherapeutics will report its Q2 and first half 2025 financial results on Thursday, August 7, 2025.

What time is the Iovance Biotherapeutics Q2 2025 earnings call?

The earnings conference call and webcast will take place at 4:30 p.m. ET on August 7, 2025.

How can I access Iovance Biotherapeutics (IOVA) Q2 2025 earnings webcast?

The webcast can be accessed through the Investors section at IR.Iovance.com or by registering at the provided webcast link. The recording will be available for one year.

What does Iovance Biotherapeutics (IOVA) specialize in?

Iovance Biotherapeutics specializes in developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer patients.